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1. Introduction 
Type 1 diabetes is an autoimmune disease leading to the destruction of pancreatic cells. 
The reduction of cell mass results in insulin deficiency that leads to a failure of glucose 
homeostasis with increased levels of glucose in blood. Hyperglycemia which per se is 
detrimental for the organism and may be life-threatening, may in the long term associate 
with chronic complications involving blood vessels and nerves. The gold standard treatment 
for diabetes patients aimed to reach a tight control of glycemia, relies on intensive insulin 
therapy based on multiple daily injections or continuous subcutaneous infusion of insulin. A 
tight control of glycemia reached with such regimens was shown to significantly reduce the 
incidence of microvascular complications in respect to the conventional insulin therapy. 
Nevertheless, to reach an optimal control of blood levels may prove to be difficult when 
compared to the physiological condition where this is guaranteed by the pancreatic  cells 
(Suckale, 2008). Therefore, preservation of cell mass could be an important therapeutic 
target to reduce microvascular complications and to improve the glycemia control (Gonez & 
Knight, 2010). It is generally accepted that the endocrine pancreas has some regenerative 
capabilities, although it is still debated which cells are involved in cell turnover. In rodents 
the capability of adult pancreas to increase cell mass has been documented in 
physiological conditions and after injury. The understanding of mechanisms involved in  
cell turnover may therefore be relevant to design new therapeutic strategies aimed to 
maintain a  cell mass or to favour regeneration of  cells. These strategies however, should 
take to account the problem of recurrent autoimmunity that in type 1 diabetes not only 
impairs the original cell mass, but may also limit the regenerative process. Indeed, 
autoimmune T lymphocytes may kill the cells newly formed in response to injury (Fan & 
Rudert, 2009).  
2.  cell regeneration: Contribution of stem/progenitor cells or replication of  
 cell? 
The physiological turnover of the long-lasting endocrine cells of pancreas requires the 
generation of new cells even with a very slow kinetic.  
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The organ growth after birth requires a coordinated increase in the number of constitutive 
cells. Moreover, in the adult body most of the tissues and organs have the ability to replace 
the cells that die for physiological senescence or following limited injury. The source of 
newly formed cells may derive from resident stem/progenitor cells or from the ability of 
differentiated cells to re-entry into cell cycle and replicate themselves. The prevalence of 
these two mechanisms varies in different organs and tissues; however, they may result in 
the restoration of the original tissue conformation and function. We therefore should expect 
that also the endocrine pancreas retains the ability of regeneration in appropriate 
physiological conditions. The nature and the location of the cells involved in such processes, 
as well as the mechanisms involved in the activation of the regenerative processes, still 
remain largely unknown.  
The concept of “stem cell” implies the ability of unlimited self renewal and of high 
multilineage differentiation potential into different types of mature cells. Therefore, stem 
cells play fundamental roles in organogenesis during embryonic development, and in the 
adult are responsible for the growth, homeostasis and repair of many tissues.  
In the haematopoietic system, the intestine and the skin, tissues that require a high cell 
turnover, the stem cells are critical for maintaining their homeostasis. However, adult 
stem/progenitor cells are present in the majority of tissues and organs of mammalian 
organisms, including the central nervous system (Reynolds & Weiss, 1992), retina (Tropepe 
et al., 2000), skeletal muscle (Jackson et al., 1999), liver (Herrera et al., 2006) and kidney 
(Bussolati et al., 2005).  
In tissues with a low rate of cell turnover, such as the kidney, the lung, the skeletal muscle 
and the liver, the resident stem cells may activate after injury and participate in tissue 
repair. Tissue resident stem cells preferentially generate differentiated cells of the tissue of 
origin, suggesting a relevant role in the postnatal growth of organs, in physiological 
turnover and in tissue repair. Tissue-resident adult stem cells are thought to co-localize with 
supporting cells within specific regions or specialized microenvironments in each 
tissue/organ, called stem cell niche (Jones & Wagers, 2008; L. Li et al., 2005; Moore & 
Lemischka, 2006). In bone marrow the haematopoietic stem cells (HSC) are located in the 
endosteal niche, associated with the osteoblasts of the inner surface of the cavities of 
trabecular bone that could provide factors able to regulate number and function of HSC 
(Mitsiadis et al., 2007) and in the perivascular area of sinusoids that could ensure 
homeostatic blood cell production and prompt responses to haematological stresses (Kiel et 
al., 2005). The other stem cells present in bone marrow are the mesenchymal stem cells 
(MSC), undifferentiated adult stem cells of mesodermal origin, which localize in 
perivascular areas in the bone marrow in close association with HSC (Shi & Gronthos, 2003) 
and that have the capacity to differentiate into cells of connective tissue lineages, including 
bone, fat, cartilage and muscle (Y. Jiang et al., 2002).  
Other stem cell niches detected in mammals (da Silva Meirelles et al., 2008; L. Li & Xie, 2005) 
are the epithelial stem cell niche in skin that resides in the bulge area of the hair follicle 
beneath the sebaceous gland (Cotsarelis et al., 1990; Niemann & Watt, 2002; Sun et al., 1991), 
the intestinal stem cell niche located at the fourth or fifth position above the Paneth cells 
from the crypt bottom (Booth & Potten, 2000; He et al., 2004; Sancho et al., 2004) and the 
neural stem cell niche at the subventricular zone and the subgranular zone of the 
hippocampus where neural stem cells could reside and support neurogenesis in the adult 
brain (Doetsch et al., 1999; Temple, 2001). 
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A problem in the identification of tissue resident stem cells is that we do not know specific 
markers allowing tracing of pluripotent stem cells in various tissues. Therefore, resident 
stem cells are mainly defined by functional in vitro assays using cultured cells, and their in 
vivo exact localization and function remains elusive. Several studies suggest that the adult 
tissue resident stem cells belong to the MSC lineage (da Silva Meirelles et al., 2006). The 
minimal criteria to define human MSC established by Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy (da Silva Meirelles et al., 2008; 
Dominici et al., 2006), include cell positivity for CD105, CD73, and CD90 and negativity for 
CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR as well as osteo-, chondro-, and 
adipogenic-differentiation capabilities.  
A perivascular location for MSC has been suggested, correlating these cells with pericytes 
providing an explanation for the presence of MSC virtually in all vascularized tissues (da 
Silva Meirelles et al., 2006). The perivascular zone may act as a MSC niche in vivo, where 
microenvironment factors may modulate their phenotype with transition to progenitor and 
mature cells. For many years the concept of niche has been associated with a hierarchical 
nature of stem cells that undergoing asymmetric division insure self-renewal and generation 
of a progeny with progressive loss of proliferative potential and gain of differentiated 
characteristics (Till et al., 1964). More recently, a continuum model of stem cell biology has 
been proposed (Colvin et al., 2004; Quesenberry et al., 2005). It has been postulated that the 
phenotype of stem cells is labile, it varies with position in the cell cycle and that it is 
reversible (Colvin et al., 2007). This cell-cycle reversibility is at the basis of the continuum 
model of stem cell biology, in which the phenotype of stem cells is reversibly changing 
during the cell cycle transit awaiting for a terminal-differentiating stimulus at a cycle-
susceptible time. In this model the status of the cell cycle and the exposure to environmental 
factors play critical roles in the acquirement of different phenotypes by the same cell in 
different functional states (Quesenberry et al., 2007). Recently, Quesenberry and Aliotta 
proposed that the so-called niche consists in areas of influence which are continually 
adjusting to individual circumstances (Quesenberry & Aliotta, 2008).  Based on these 
considerations, the refined regenerative system in mammalians does not need to position in 
each organ different stem cell types but it would be sufficient to maintain few 
undifferentiated cells with self-renewal capability that depending on the circumstances may 
vary their phenotype to replace the loss of differentiated cells. On the other hand, 
differentiated cells may re-acquire an undifferentiated phenotype and re-entry in to cell 
cycle first to restore the cell mass and subsequently to re-differentiate and restore functional 
integrity. In this context, the exchange of genetic information among cells by microvesicles 
in a defined environment plays a critical role in modulating plasticity of stem cells as well as 
the response of differentiated cells to injury (Deregibus et al., 2010).  
Studies on  cell proliferation in humans are limited, but there is evidence that this process 
occurs at relatively high levels in the first 2 years of life declining thereafter with the 
possibility, at least in animals, of re-induction under conditions of insulin-resistance, such as 
pregnancy or obesity. (Meier et al., 2008). This suggests that  cells may retain an intrinsic 
capacity to replicate. 
In the adult, endocrine pancreas cells are considered to have a very low turnover. 
However, albeit quite slowly, cells undergo senescence and should be continuously 
replaced by newly formed cells. By combining abdominal CT scans and morphometric 
analysis of human pancreatic tissue, Meier et al reported that the cell mass expands by 
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several fold from birth to adulthood as result of an expansion in size of islets rather than an 
increase in number of islets (Meier et al., 2008). The increase in  cell number per islet 
mainly occurs in young children in coincidence with the growth of the organ size. Cnop et al 
provided evidence for a long lifespan and low turnover of human islet  cells estimated by 
mathematical modelling of lipofuscin accumulation (Cnop et al., 2010). Human cells, 
unlike those of young rodents, are long-lived and in the adult human  cell population is 
mainly established in the first 20 years of life. Dor et al using a method for genetic lineage 
tracing to determine the contribution of stem cells to pancreatic  cell neogenesis showed 
that pre-existing  cells, rather than pluripotent stem cells, are the major source of new  
cells during adult life and after pancreatectomy in mice (Dor et al., 2004). These results 
suggest that terminally differentiated  cells retain, at least in mice, a significant 
proliferative capacity in vivo.  Nir et al used a transgenic mouse model to study the 
dynamics of  cell regeneration from a transiently induced diabetic state (Nir et al., 2007). 
Lineage tracing analysis in this model indicated that enhanced proliferation of surviving  
cells played the major role in regeneration. These studies provided evidence that adult 
pancreatic  cells are formed by self duplication rather than stem cell differentiation (Dor et 
al., 2004; Nir et al., 2007). On the other hand there are studies suggesting that regenerated  
cells derive from precursors located within pancreatic ducts in the proximity of islets (Juhl et 
al., 2010). The origin from these precursors has been demonstrated in rodent models of 
pancreatic damage (Bonner-Weir et al., 2004; Xu et al., 2008). Monitoring the expression of 
Neurogenin 3 (Ngn3), the earliest islet cell-specific transcription factor in embryonic 
development, Xu et al showed activation of  cell progenitors located in the ductal lining in 
injured adult mouse pancreas (Xu et al., 2008). They found that differentiation of the adult 
progenitors is Ngn3 dependent and generates  all islet cell types, including glucose 
responsive  cells that proliferate, both in situ and when cultured in embryonic pancreas 
explants. This study suggests that multipotent progenitor cells present in the pancreas of 
adult mice can increase the functional  cell mass by differentiation and proliferation rather 
than by self-duplication of pre-existing  cells only. Li et al investigated whether after partial 
pancreatectomy in adult rats, pancreatic-duct cells serve as a source of regeneration by 
undergoing a dedifferentiation and redifferentiation (W.C. Li et al., 2010). The Authors 
detected after pancreatectomy an early loss by the mature ducts of the ductal differentiation 
marker Hnf6, followed by the transient formation of areas composed of proliferating 
ductules, called foci of regeneration. These ductules expressed markers of the embryonic 
pancreatic epithelium Pdx1, Tcf2 and Sox9 (W.C. Li et al., 2010). Since foci subsequently 
form new pancreatic lobes, it was suggested that these cells act as progenitors of the 
regenerating pancreas. Islets in foci initially resemble embryonic islets as they transiently 
expressed the endocrine-lineage-specific transcription factor Ngn3 and lacked of MafA 
expression and contained low percentage of  cells. The numbers of MafA(+) insulin(+) cells 
progressively increased with the maturation of foci (W.C. Li et al., 2010). Based on these 
observations, it was suggested  that adult pancreatic duct cells may recapitulate aspects of 
embryonic pancreas in response to injury (W.C. Li et al., 2010). This mechanism of 
regeneration implicates the plasticity of the differentiated cells within the pancreas.  
As schematized in figure 1, after injury cells may be replaced by replication of  cells or 
from differentiation of stem cells (SC) localized within the islets or in exocrine pancreatic 
tissues (ductal and acinal cells). After extreme loss of  cell mass, glucagon producing  cells 
may transdifferentiate in  cells. A possible contribution to  cell neogenesis comes from 
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bone marrow derived stem cells of both haemopoietic (BM-derived HSC) and mesenchymal 
(BM-derived MSC) origin. These cells act by a paracrine mechanism releasing factors that 
favour tissue repair. Moreover, transdifferentiation of ductal and acinal cells may generate 
insulin secreting cells. 
 
 
Fig. 1. Mechanisms potentially involved in  cell neogenesis. 
The discrepancy in identification of cells that in the adult sustain  cell neogenesis, may 
result from the differential contribution in condition of physiological turnover and in 
condition of injury where the regenerative processes are accelerated and cells other than 
insulin producing  cells are involved to insure a reparative process. The study of Thorel et 
al showing the conversion of adult pancreatic  cells into  after extreme  cell loss stands in 
this line of interpretation (Thorel et al., 2010). In this study the Authors used in vivo genetic 
approaches to obtain near total  cell loss without autoimmunity combined with cell lineage 
tracing. For this purpose, they created a model of inducible, rapid β cell removal (>99%) by 
administration of diphtheria toxin (DT) in transgenic mice in which the DT receptor was 
expressed only in  cells (Thorel et al., 2010). In transgenic mice the systemic administration 
of DT permitted a specific cell ablation by apoptosis (Saito et al., 2001). In this model, β cell 
regeneration was monitored in combination with cell lineage tracing to investigate the 
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origin of newly formed β cells. The results obtained showed that the adult pancreas can 
generate new β cells after their near total loss, mainly by the spontaneous reprogramming of 
glucagon-secreting  cells (Saito et al., 2001). Therefore,  cell replication may account for 
maintaining homeostasis, whereas transdifferentiation of other cell types could be required 
after injury to replace the lost cells.  
Summarizing these studies, one can envisage a scenario in which  cells may replicate 
themselves to maintain homeostasis (Dor et al., 2004), tissue specific precursors localized 
within pancreatic ductal cells generate  and  cells after pancreatic injury and glucagon 
secreting  cells can transdifferentiate into  cells to repair an extremely severe selective  
cell loss. Translation of these experimental studies in humans may be difficult without the 
help of lineage tracing or of specific cellular markers.  
3.  cell mass in type 1 and type 2 diabetes 
Despite the evidence of some turnover in adult humans and the apparent capacity of 
endocrine pancreatic  cells to regenerate throughout life, patients with type 1 as well as 
type 2 diabetes have substantial deficit in  cell mass, approximately 99% in long-standing 
type 1 diabetes and 65% in long-standing type 2 diabetes. This loss of  cells implies that 
restoration of endogenous insulin secretion might be accomplished through replacement or 
regeneration of islet cells.  
The  cell deficit in type 1 diabetes is related to the established autoimmune destruction of 
the target cells. However, several lines of research indicate that some  cell regeneration 
may occur in recent onset type 1 diabetic patients (Willcox et al., 2010) and even in patients 
with long-standing type 1 diabetes (Meier et al., 2005). The failure of  cell regeneration in 
type 1 diabetes may be related to the increased vulnerability of the newly forming  cells to 
apoptosis induced by inflammatory cytokines (Meier et al., 2006). 
Other mechanisms, involved in all forms of diabetes,  include the hyperglycemic induction 
of the nitric oxide synthase (NOS)-dependent mechanisms in islet microendothelium, with 
production of the vasoactive mediator nitric oxide (NO) (Suschek et al., 1994), endothelial 
cell loss and vasculature disruption (Zanone et al., 2008). NO is in fact increased in 
hyperglycemic conditions, and has an established direct islet cytotoxicity and potentially 
impairs insulin release (Steiner et al, 1997; Suschek et al., 1994; Kröncke et al., 1993). Islet 
microendothelial cells are also source of the proinflammatory cytokine IL-1 under 
hypeglycemic conditions, independently of any viral or immune-mediated process. IL-1 
impairs insulin release in human islet, induces Fas expression enabling Fas-mediated 
apoptosis and  IL-1 is thus implicated as a mediator of glucotoxicity (Maedler et al., 2001; 
Loweth et al., 1998). The metabolic mechanisms by which hyperglycemia initiates apoptosis 
in vascular endothelium are incompletely understood. These mechanisms include oxidative 
stress, increased intracellular Ca++, mitocondrial dysfunction, changes in intracellular fatty-
acid metabolism, and impaired phosphorylation of the protein kinase Akt (Favaro et al., 
2008). Akt signaling pathway plays a pivotal role in preventing apoptosis in a variety of 
settings (Datta et al., 1999), and, in particular, Akt activation is crucial for the ability of 
factors such as insulin, IGF-I and VEGF to inhibit apoptosis in cultured endothelium (Jung 
et al., 2000). Recent data highlight the Akt role also in insulin-mediated glucose transport 
and pancreatic  cell mass and function (Bernal-Mizrachi et al., 2004; Elghazi et al., 2006). As 
for type 2 diabetes, the progressive increase in glucose levels that characterizes its natural 
history has been claimed to be due to gradual reduction of function and mass of  cells, and 
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a significant reduction in  cell mass is clearly established in Type 2 diabetes (Donath & 
Halban, 2004; Weir & Bonner-Weir, 2004). The same mechanisms of glucotoxicity reported 
are involved, together with dyslipidaemia. In murine models of type 2 diabetes, short-term 
hyperglycemia has been shown to increase islet capillary blood pressure and perfusion, in a 
glucose dependent and reversible pathway, possibly mediated by a NOS–dependent 
mechanism (Bonner-Weir, 2004; Carlsson et al., 1998). However, with age, persistent 
hyperglycemia induces islet hypoperfusion. Inducible NOS (iNOS) increases the islet blood 
perfusion also in prediabetic low dose streptozotocin-treated mice, a model of type 1 
diabetes (Carlsson et al., 2000). Increased islet capillary flow and pressure could, over time, 
contribute to the damage of the islet endothelium and thickening of the capillary wall, thus 
decreasing the islet perfusion. The hyperglycemia-induced NO production by the 
endothelium could also result cytotoxic to the islets and directly impair insulin release. 
In Zucker diabetic fatty rats, a model of type 2 diabetes, it has been shown that changes in 
the islet vasculature play a key pathogenetic role in the development of diabetes (X. Li et al., 
2006). In a biphasic pattern, an early vascular hyperplasia was followed by endothelial cell 
loss and vasculature disruption, in parallel to progressive islet failure. 
4. Islet transplantation as strategy for  cell replacement  
Allogenic pancreatic islet transplantation has become a suitable therapeutic option for the 
treatment of patients with unstable type I diabetes after the introduction of the Edmonton 
Protocol based on the optimization of islet isolation techniques and the development of a 
rapamycin-based glucocorticoid-free immunosuppressive regimen (Ricordi, 2003; Shapiro et 
al., 2000, 2003, 2006). However, after 5 years only 10% of the recipients were insulin 
independent (Ryan et al., 2005; Shapiro, 2006). In addition, although a sufficient islet mass 
can be obtained from good quality pancreata, to achieve insulin independence usually are 
needed islet preparations derived from multiple donors (Biancone & Ricordi, 2002). 
Therefore, this procedure is limited by the supply of cadaveric donors. Moreover, several 
factors may be responsible of the progressive dysfunction of transplanted islets. After an 
initial islet mass loss following the intraportal infusion, due to an inflammatory reaction, 
engraftment requires efficient islet revascularization by a chimeric vascular tree formed by 
host and recipient endothelial cells (Brissova et al., 2004). A poor vascular engraftment is 
one of the main causes of islet loss. Other factors that concur to islet loss include the 
exposure of islets to increased lipid levels, a side effect of immunosuppressive therapy 
based on mTOR inhibitors (Hafiz et al., 2005; Pileggi et al., 2006). Exposure to high-dose of 
calcineurin inhibitors (CNI) is recognized to induce direct β cell toxicity and functional 
impairment. The antiproliferative effects of mTOR inhibitors and CNI inhibit tissue 
remodelling and reduce β cell self-renewal (Nir et al., 2007). Moreover, the anti-angiogenic 
activity of rapamycin is a potential limitation of the current immunosuppressive protocols, 
that may be particularly detrimental in the early engraftment phase (Cantaluppi et al., 2006). 
Therefore, to overcome these problems it is necessary to improve the recovery and quality of 
islet cells from a single-donor pancreas and to develop strategies allowing the inhibition of 
inflammatory reactions, the improvement of islet vascularization and of islet engraftment 
using safer and less cytotoxic immunomodulatory approaches (Mineo et al., 2009; Pileggi et 
al., 2006; Ricordi, 2003). Recently, increased islet yields have been obtained by improving 
techniques of pancreas recovery and preservation and  of islet isolation and purification 
(Pileggi et al., 2006;Ricordi, 2003). On the other hand, peritransplant interventions based on 
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combination therapies have been proposed to inhibit allo- and auto-immune response 
minimizing the side effects and favoring development of T regulatory cells (Treg) to 
maintain long term tolerance and to favor  cell regeneration. Targeting the costimulatory 
molecules involved in T-cell activation and/or adhesion molecules by immunomodulatory 
agents now available for clinical applications could be an option to reduce the side effects of 
immunosuppression and the islet toxicity and to achieve specific immune tolerance (Ricordi 
& Strom, 2004). Several experimental studies suggest that a combined islet transplant and 
cell therapy with bone marrow–derived cells, mesenchymal cells, Treg, and tolerogenic 
dendritic cells may modulate recipient immune response and increase the engraftment and 
long term survival of islets (Mineo et al., 2008). This possibility is supported by recent 
clinical trials demonstrating stable mixed haematopoietic chimerism and/or improved 
tolerance in kidney allograft recipients using nonmyeloablative conditioning and donor 
haematopoietic stem cell infusion  (Sykes, 2009). 
Another factor limiting successful islet engraftment is the inflammatory reaction that takes 
place in the liver after portal vein infusion of islets. This observation led to experiments of 
co-transplantation of islets with bone marrow-derived mesenchymal stem cells to take 
advantage of the anti-inflammatory action of these cells (Ito et al., 2010).  
To improve islet vascularization is also a must for a better engraftment of islets. It has been 
shown that bone marrow-derived endothelial progenitor cells (EPC) isolated from 
peripheral blood specifically localize within sites of endothelial injury inducing a 
regenerative program. EPC are able to chimerize with donor vessels in transplanted organs, 
suggesting a putative role of these cells in graft revascularization (Schuh et al., 2008¸ 
Koopmans et al., 2006). EPC are recruited to the pancreas in response to islet injury and 
EPC-mediated pancreas neovascularization may facilitate the recovery of injured  cells 
improving islet allograft function (Mathews et al., 2004). In a murine model of islet 
transplantation, the increase of EPC in the peripheral circulation obtained by mobilization 
with granulocyte-macrophage colony-stimulating factor has been associated with higher 
vascular density and engraftment (Contreras et al., 2003). Therefore, the identification of 
factors able to enhance neoangiogenesis may increase the success of islet transplantation.  
Another goal of combination therapies is to preserve islet function after detection of graft 
dysfunction (Froud et al., 2008). For this purpose it has been suggested, for instance, the use 
of exenatide, glucagon-like peptide synthetic analog, anti-tumor necrosis factor  agents or 
immunomodulatory therapy (Faradji et al., 2008; Froud et al., 2008). However, the recently 
released results of two trials addressing strategies of combination therapies are 
disappointing. The phase three trial based on combination of anti-CD25 mAb (Daclizumab) 
that blocks IL-2 signalling pathway in activated T cells without interferring with Treg, in 
combination with mycophenolate mofetil that bloks the de novo purine synthesis in T and B 
lymphocytes, reported no improvement of  cell preservation (Gottlieb et al., 2010). The 
anti-CD25 mAb was tested in another trial in association with exenatide. Also in this trial 
the improvement of  cell function was not observed (Rother et al., 2009). Several other 
phase II-III National Institutes of Health (NIH)–sponsored randomized trials in islet 
transplantation alone and in islet-after-kidney transplantation are currently under 
evaluation by the Clinical Islet Transplantation Consortium 
(http://www.citisletstudy.org/). An alternative to allow long term survival of islets after 
transplantation is the development of efficient encapsulation techniques aimed to guarantee 
immune-isolation, an adequate exchange of nutrients to islet cells and release of insulin 
(Calafiore et al., 2006). This kind of approach may protect from cell-mediated rejection of 
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implanted islets, although soluble mediators may still reach  cells and induce cell death. On 
the other hand, this strategy might allow full maturation of embryonic stem cells into 
glucose sensitive insulin secreting  cells. Indeed, human embryonic stem cells 
differentiated into pancreatic endoderm could be encapsulated in a protective device before 
transplantation (D'Amour et al., 2005; Kroon et al., 2008). Experiments in NOD mice 
demonstrated that encapsulated human  cell precursors may generate functional insulin 
producing cells after implantation improving diabetes (S.H. Lee et al., 2009). As an 
alternative, ongoing studies are evaluating the use of encapsulated porcine islets to correct 
type 1 diabetes (Elliott et al., 2007). Preliminary studies in humans showed long term 
survival of xenotransplantation of porcine neonatal islets and Sertoli cells using a 
technology to provide an immune protective environment (Valdes-Gonzales et al., 2005). A 
vascularized chamber model allowing tissue growth in threedimension under influence of 
hypoxia that triggers angiogenesis has been developped in mouse (Cronin et al., 2004) and 
rat (Mian et al., 2000; Tanaka et al., 2000). Vascularized chambers containing syngenic islets 
were used to improve glucose control in diabetic mice (Hussey et al., 2009). In this study 
islets were transplanted into prevascularized chambers implanted on the epigastric pedicle 
in the groin of diabetic mice resulting in a significant reduction in blood glucose levels and 
improvement of glycemic control. This study suggests that islet survival and function are 
enhanced by prevascularization of tissue engineering chambers before islet transplantation 
(Hussey et al., 2009). Opara et al. reported a new design of a bioartificial pancreas 
comprising islets co-encapsulated with angiogenic protein in permselective multilayer 
alginate-poly-L-ornithine-alginate microcapsules and transplanted in an omentum pouch in 
diabetic experimental animals (Opara et al., 2010). A great effort is invested to improve the 
encapsulation techniques to avoid clogging of the device that may reduce the influx of 
nutrients and glucose and impair the insulin efflux. Teramura & Iwata recently reviewed the 
obstacles and the new techniques to overcome these problems, such as conformal coating 
and islet enclosure with cells (Teramura & Iwata, 2010). 
In consideration of the shortage of pancreata for islet transplantation and of the side effects 
of current immunosuppressive protocols, the research has been focused on the possible 
development of alternative sources of functional β cells. The ideal approach to overcome the 
current inadequate supply of human pancreatic islet cells for transplantation is the 
availability of an unlimited source of transplantable insulin-producing cells. The potential of 
adult and embryonic stem cells to generate islet cells as well as development of appropriate 
conditions for expansion and differentiation to β cells of pancreatic islet cell precursors or of 
cells that share common embryonic origin such as liver cells is under intense investigation 
(Mineo et al., 2009). Finally, xenogeneic islet transplantation remains a viable therapeutic 
option for the future (Ricordi, 2003).  
5. In search for alternative sources of  cells 
The consideration that stem cells play a crucial role to self-renewal in physiologic and 
pathologic conditions in the endocrine pancreas (Bouvens, 2006; Sarvetnick et al., 2007a, 2007b) 
prompted researchers to develop SC-based therapy to stimulate β cell regeneration.  
In the last years, a variety of approaches have been employed to induce β cell neogenesis using 
pluripotent stem cells (embryonic stem cells or induced pluripotent stem cells), multipotent 
adult stem cells such as the hepatic oval cells or terminally differentiated cells such as the 
exocrine pancreatic cells (Yechoor & Chan, 2010). Brolén et al investigated the potential of 
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human embryonic stem cells to differentiate into  cells (Brolen et al., 2005). They found that 
signals from the embryonic mouse pancreas induce differentiation of human embryonic stem 
cells into insulin-producing  cell-like cells. Human embryonic stem cells (hESC) under two-
dimensional growth conditions spontaneously differentiated in Pdx1(+)/Foxa2(+) pancreatic 
progenitors and Pdx1(+)/Isl1(+) endocrine progenitors but not in insulin-producing cells. The 
differentiation of  cell-like cell clusters required co-transplantation with the dorsal pancreas 
from mouse embryos. hESC-derived insulin(+) cell clusters exhibited several features of 
normal  cells, such as synthesis (proinsulin) and processing (C-peptide) of insulin and nuclear 
localization of key  cell transcription factors, including Foxa2, Pdx1, and Isl1 (Brolén et al., 
2005). Insulin-producing islet-like cells were also generated from human embryonic stem cells  
under feeder-free conditions (Jiang et al., 2007). Cell aggregates formed in the presence of 
epidermal growth factor, basic fibroblast growth factor, and noggin were finally matured in 
the presence of insulin-like growth factor II and nicotinamide. The temporal kinetic of 
pancreas-specific gene expression was considerably similar to that of in vivo pancreas 
development. The final population contained cells representative of the ductal, exocrine, and 
endocrine pancreas. Ricordi et al reported a diabetes reversal in mice by embryonic-derived 
stem cells (Ricordi & Edlund, 2008). They showed that endodermal-derived embryonic stem 
cells were able to differentiate into cells that expressed typical pancreatic endodermal markers 
and, once transplanted in diabetic mice, these cells showed a diffuse staining for insulin, other 
hormones and markers of fully differentiated β cells (Ricordi & Edlund, 2008). The therapy 
with embryonic stem cells represents an exciting approach towards  cell regeneration and 
function. So far, the most promising data are from a group of NovoCell who demonstrated the 
generation of glucose-responsive insulin-secreting cells in vivo by pancreatic endoderm 
derived from human embryonic stem cells into immune-deficient mice (Kroon et al., 2008). 
However, several problems remain to be solved, such as the reproducibility of the advance, 
the protection of the engrafted cells against tumor formation and immune-protection that 
could be achieved by encapsulation devices. Recently, Matveyenko et al tried to reproduce and 
extend the studies of NovoCell by the implantation of human embryonic stem cell-derived 
pancreatic endoderm into athimic nude rats, analysing the metabolic parameters of insulin 
sensitivity and glucose-stimulated insulin secretion to verify the development of viable 
glucose-responsive insulin secreting cells. The implantation was assessed into the epididymal 
fat pads of the athymic nude rats or subcutaneously into Theracyte encapsulation devices for 
20 weeks (Matveyenko et al., 2010). The data resulting from this study not completely 
confirmed the development of islet-like structures from human embryonic stem cells 
differentiated to pancreatic endoderm, since the extent of endocrine cell formation and 
secretory function was insufficient to be clinically relevant given that human C-peptide and 
insulin were detectable at very low levels, no increase in human C-peptide/insulin levels after 
glucose challenge and no development of viable pancreatic tissue or efficient insulin secretion 
by implantation in the encapsulation devices were present (Matveyenko et al., 2010).  
Nevertheless, because the use of embryonic stem cells is burdened with the limited access to 
embryonic tissues and with the complex ethical concerns involved with the use of 
embryonic cells, more attention has been focused on adult stem cells. We found that stem 
cells derived from normal adult human liver (HLSC) with multiple differentiating 
capabilities distinct from those of oval stem cells may generate islet-like structures. HLSC 
expressed several MSC markers such as CD73, CD90, CD29, CD44 and the stem cell marker 
nestin (Herrera et al., 2006). At variance of MSC, HLSC did not express -SMA and 
expressed liver tissue-specific proteins such as AFP, a marker of hepatocyte precursors, and 
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human albumin, suggesting a partial hepatocyte commitment. At variance with oval cells, 
the HLSC isolated from normal adult liver, did not express the CD34, c-kit and CK19 
markers, and were pluripotent. Moreover, the HLSC were able to differentiate in 
appropriate conditions into pancreatic insulin producing cells (Herrera et al., 2006).  When 
cultured in DMEM with high glucose content (23mM) for one month followed by 5-7 days 
of culture in the presence of 10 mM nicotinamide, HLSC formed small spheroid cell clusters 
positive for human insulin and Glut2 which is a glucose transporter that has been suggested 
to function as a glucose sensor in pancreatic  cells (L. Yang et al., 2002). Moreover, HLSC 
under this differentiating condition, were positively stained with the Zn-chelating agent 
dithizone, that is specific for the insulin containing granules (Shiroi et al., 2002). It has been 
recently shown that adult human pancreas contains rare multipotent stem cells that express 
insulin (Smukler et al., 2011). 
Several studies demonstrate that the  cell phenotype can be induced both in vitro and in 
vivo by transfection of pancreatic transcription factors into the liver that develops from the 
same embryological origin of pancreas (Kojima et al., 2003; Lemaigre & Zaret, 2004; Nagaya 
et al., 2009).  
The potential of bone marrow derived MSC has also been explored. Genetically modified 
MSC by recombinant PDX-1 adenovirus or by non-virus gene transfection, were able to 
express insulin sufficient to reduce blood glucose in the streptozotocin mouse model of 
diabetes (Y. Li et al., 2007). The differentiated PDX-1+ human MSC expressed multiple islet-
cell genes such as neurogenin3 (Ngn3), insulin, GK, Glut2, and glucagon, produced and 
released insulin/C-peptide. After transplatation into STZ-induced diabetic mice the 
differentiated PDX-1+ human MSC induced within 2 weeks euglycemia and maintained it 
for at least 42 days. These findings suggest that appropriately modified MSC may allow 
enrichment of human  cells and represent a possible source for cell replacement therapy in 
diabetes (Y. Li et al., 2007). 
Human umbilical cord blood contains several types of stem/precursor cells. Recent studies 
indicate the possibility to obtain multipotent stem cells from umbilical cord blood able to 
confer protection to  cells and to stimulate  cell neogenesis (Zhao & Mazzone, 2010). Islet-
like cell clusters were obtained from MSC derived from humbilical cord vein. However, 
they secreted very low amounts of insulin in vitro (Chao, 2008). Denner et al showed that 
directed engineering of human cord blood stem cells may produce C-peptide and insulin 
(Denner et al., 2007).  
A better understanding of the mechanisms of β cell regeneration may provide further 
insight for development of cell based therapeutic approaches. Besides the potential 
contribution of circulating and resident stem cells, the transdifferentiation of existing 
pancreatic cells such as pancreatic ductal/acinar cells into insulin secreting cells could be 
potentially exploited (Baeyens et al., 2005; Cantaluppi et al., 2008; Minami et al., 2005; 
Rosenberg, 1995).  
The successful differentiation of stem cells into  cells may prove not to be easy. The 
secretion of insulin in physiological concentration in response to glucose concentration is the 
goal to be achieved. One of the more difficult tasks is to maintain an intact coupling of 
stimulus-secretion in order to obtain a regulated insulin secretion to keep physiological 
glucose concentration.  
Another pre-requisite for  cell replacement therapy is to obtain a non limiting source of 
cells possibly derived from the patient himself to avoid the allo-immune response 
(Wagner et al., 2010). The possibility of reprogramming patient’s own cells could be an 
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approach to these requirements. This was rendered possible by the  discovery that 
induced pluripotent stem cells (iPS) can be generated from adult human somatic cells 
such as fibroblasts by transfection with selected genes  encoding for transcription factors 
able to confer the characteristics of pluripotency to cells (Takahashi & Yamanaka, 2006; 
Yamanaka et al., 2007). iPS share the same differentiation potential of embryonic stem 
cells and they can differentiate into cells of different lineages including insulin producing 
cells. Tateishi et al tried to generate human iPS cells by retroviral expression of human 
Oct4, Sox2, Klf4 and c-Myc in the human foreskin fibroblast cells and tested the 
differentiation potential of human iPS cells into insulin secreting islet-like clusters, 
demonstrating that iPS cells derived from human skin cells can be differentiated into 
pancreatic islet-like cluster cells.  These cluster cells were shown to contain C-peptide-
positive and glucagon-positive cells and, more importantly, to release the C-peptide upon 
glucose stimulation (Tateishi et al., 2008). iPS cells were also generated from patients with 
type 1 diabetes by reprogramming their adult fibroblasts with three transcription factors 
(OCT4, SOX2, KLF4). The iPS generated from patients were shown to differentiate into 
insulin-producing cells (Maehr et al., 2009).  A proof of principle for potential clinical 
applications of reprogrammed somatic cells in the treatment of diabetes type 1 or 2 was 
provided  by Alipio et al who were able to reverse hyperglycemia in diabetic mouse 
models using iPS-derived pancreatic  like cells (Alipio et al., 2010). iPS could overcome 
the ethical issues and the immunogenicity of embryonic stem cells. The possibility to use 
iPS individually tailored for each patient is certainly appealing. However, several 
problems of bio-safety must be solved before iPS enter in clinical use. These include an 
aberrant or incomplete differentiation and a tumorigenic potential. Reprogramming cells 
typically requires integration of genes such as c-MYC, OCT4 AND KLF4 that are known to 
be oncogenic and may favour development of tumors (Miura et al., 2009). Although after 
reprogramming the transgenes undergo silencing, it is always possible a reactivation. 
Therefore, the research in this field is actively searching for alternative strategies to 
induce pluripotency.  
6. Stem cell therapy to counteract the autoimmune destruction of  cells 
Assuming that we could generate pluripotent stem cell lines for each individual patient and 
that after infusion they would be able to restore the  cell mass, we still have to face the 
problem of recurrent autoimmunity. The autoimmune destruction of islet  cells by reactive 
T lymphocytes not only plays a role in the establishment of type 1 diabetes but also impairs 
an efficient regenerative process. Newly forming  cells show increased vulnerability to 
apoptosis induced by inflammatory cytokines (Meier et al., 2006), explaining the failure of  
cell regeneration in type 1 diabetes. Therefore, newly generated  cells are systematically 
killed as they acquire the mature phenotype, thus impairing the regenerative attempts in 
type 1 diabetic patients. Furthermore, therapeutic intervention studies in new onset type 1 
diabetes involving broadly immunosuppressive agents, such as cyclosporin A, failed to 
produce lasting remission, demonstrating the inherent tendency of the autoimmune effector 
response in humans to recur. Therefore, it is critical that any immunemodulatory therapy 
induces tolerance to  cell antigens, while minimizing detrimental effects on host defence. 
This is strengthened by recurrence of type 1 diabetes in syngenic pancreas transplantation 
(Sutherland et al., 1984). 
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Cell-based therapeutic strategies for immunemodulation that answer to the requirement of 
safety and effectiveness are under development. The intravenous use of humanized 
antibodies against CD3 (part of the T-cell receptor complex) soon after the initial onset of 
diabetic clinical symptoms decreased the insulin requirement compared to controls without 
this monoclonal antibody therapy. However, this therapy is burdened by several adverse 
effects (Keymeulen et al., 2005; Herold et al., 2002; McDevitt & Unanue, 2008).  
Other approaches of immunemodulation included subcutaneous administration of heat-
shock protein (Raz et al., 2001) or intravenous injection of rabbit polyclonal anti T-cell 
globulin (Saudek  et al., 2004). In many of these studies a short term effective preservation of 
 cell function was observed; however, only few patients no longer required insulin 
treatment. Using human recombinant glutamic acid decarboxylase (GAD65) as therapeutic 
vaccine it was observed a preservation of C-peptide levels and a decrease in insulin dose 
requirement only in patients with very recent-onset of diabetes (Ludvigsson et al., 2008; 
Uibo and Lernmark 2008). Compelling evidence indicates the relevant role of Treg in the 
inhibition of autoimmune response. A decreased number and function of Treg have been 
reported in patients with type 1 diabetes (Roncarolo & Battaglia, 2007). Therefore, 
intervention to restore Treg function in diabetic patients is an attractive therapeutic strategy. 
Nevertheless, only few studies have shown re-establishment of Treg function in diabetes. 
Zhao et al demonstrated the possibility to correct functional defects of CD4+ CD62L Treg 
using human cord blood stem cells. This strategy allowed reversal of autoimmune diabetes 
in NOD mice (Y. Zhao et al., 2009) providing proof of principle that cord blood stem cells 
can correct function of Treg.  
Treg may act by producing IL-10 and in particular transforming growth factor-1 (TGF1), 
cytokines that are known to contribute to the induction of immunetolerance. It has been 
suggested that protection of newly generated  cells achieved by treatment with Treg 
depends on the formation of TGF1 cell ring surrounding pancreatic islands and conferring 
protection against autoimmune T lymphocytes inducing their apoptosis (Y. Zhao et al., 
2009). In a pilot study in Type 1 diabetic children based on administration of autologous 
umbilical cord blood  shortly after disease onset a lower level of HbA1c and a reduced 
insulin requirement was reported. However, none of the patients achieved insulin-treatment 
independency (Haller et al., 2007).  
Recent studies raised great interest on the immunemodulatory potential of mesenchymal 
stem cells (Le Blanc & Pittenger, 2005). MSC can modulate several T cell functions exerting 
an immunesuppressive effect. MSC that lack MHC class II molecules and do not express key 
costimulatory molecules B7-1, B7-2, CD40 and CD40L, were shown to reduce the expression 
of several lymphocyte activation markers (Aggarwal & Pittenger, 2005). The mechanism has 
been related to the induction of an anti-inflammatory phenotype in dendritic cells, naive 
and activated T cells and NK cells, and to an increase of the regulatory T cell population. 
This results not only in the inhibition of T cell proliferation to polyclonal stimuli, but also in 
inhibition of naive and memory antigen-specific T cells response to their cognate peptide 
(Krampera et al., 2003). The MSC-induced suppression has been ascribed to several soluble 
factors, including hepatocyte growth factor (HGF), TGF-1 and prostaglandin E2 (PGE2) 
(Aggarwal & Pittenger, 2005). Moreover, MSC have been shown to induce mature dendritic 
cells type 2 (DC2) to increase IL-10 secretion thus promoting anti-infammatory DC2 
signaling. Several studies suggest that MSC improve the outcome of allogenic 
transplantation and hamper graft-versus-host disease (Le Blanc et al., 2004; Ringden et al., 
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2006). Studies on the immunemodulatory potential of MSC in human type 1 diabetes are 
still lacking but it has been reported their regenerative potential in diabetic NOD/SCID 
mice leading to an increased number of pancreatic islets and  cells (R.H. Lee et al., 2006). 
We recently demonstrated that human allogenic bone marrow derived MSC can abrogate in 
vitro a pro-inflammatory Th1 response to islet antigen GAD in new onset type 1 diabetes, by 
impairing the production of IFN- and by inducing anti-inflammatory IL-4 production 
(Zanone et al., 2010). These data stimulate further studies on MSC immunemodulation in 
diabetes and open a perspective for immune-intervention strategies. The mechanisms of 
MSC interaction with the immune system cells are still controversial (van Laar & Tyndall, 
2006; Abdi et al., 2008), and include reduction of the expression of lymphocyte activation 
markers, change of the cytokine profile of dendritic cells, naive and activated T cells and NK 
cells to an anti-inflammatory phenotype, and increase of the regulatory T cell population 
(Aggarwal & Pittenger, 2005; Le Blanc et al., 2004). In the reported study in type 1 diabetes, 
MSC induced in peripheral blood mononuclear cells (PBMC) of responder patients IL-4 
producing cells and IL-4 secretion, suggesting a possible switch to an anti-inflammatory Th2 
signalling of T cells (Zanone et al., 2010). Increased IL-4 secretion has been shown in studies 
of MSC cocultured with subpopulations of PHA-stimulated immune cells (Aggarwal & 
Pittenger, 2005) but not in studies of T cells activated by encephalitogenic peptide (Zappia et 
al., 2005). Lymphocyte activation is extremely complex and it is likely that several 
mechanisms are involved in the MSC-mediated immunesuppression and that the specific 
factors may depend on the lymphocyte population tested, the stimulus used, the timing of 
analysis and the context of the immune disease.  
Further, inhibition of PGE2 production abrogated the MSC-mediated IFN- suppression, 
indicating that PGE2 secretion plays a key role in MSC-mediated immune effects, and the 
contact between MSC and PBMC enhances the production of prostaglandin E2 (Zanone et 
al., 2010). This observation suggests the requirement of both soluble factors and cell-contact 
in line with the interpretation that the immunemodulatory effects of MSC might require an 
initial cell-contact phase (Krampera et al., 2003). Nevertheless, the requirement of cell 
contact for MSC to operate their inhibition is a controversial issue, and the results reported 
in the literature may depend on the species and the type of stimulus. 
Other studies in murine diabetic models on the regenerative capabilities of MSC, showed 
that injection of MSC into immunodeficient diabetic NOD/SCID mice resulted in the 
selective homing of MSC to pancreatic islets and in an increased number of pancreatic islets 
and functioning  cells (R.H. Lee et al., 2006). Further, MSC can be influenced to 
differentiate into cells with properties of the  cell phenotype, becoming more efficient after 
transplantation in mice (M. Zhao et al., 2008). Indeed, genetically modified MSC by 
recombinant Pdx-1 adenovirus or by non-virus gene transfection, were able to express 
insulin sufficient to reduce blood glucose in the streptozocin mouse model of diabetes 
(Karnieli et al., 2007; M. Zhao et al., 2008). More recently, allogenic MSC obtained from 
diabetes-prone as well as -resistant mice and injected into NOD mice, have been shown to 
delay the onset of diabetes or to reverse hyperglycemia (Fiorina et al., 2009). This study 
indicates that the beneficial effects observed could also be ascribed to the 
immunemodulatory capacities of MSC, as for other studies focusing on MSC-induced repair 
of cell injury (Abdi et al., 2008; Morigi et al., 2004; Duffield et al., 2005). 
Studies on ex vivo expanded MSC to improve the outcome of allogenic transplantation and 
of acute graft-versus-host disease paved the way for the clinical use of MSC also in 
www.intechopen.com
 Perspectives of Cell Therapy in Type 1 Diabetes   
 
337 
autoimmune diseases. In experimental autoimmune encephalomyelitis, animal model of 
multiple sclerosis mediated by autoreactive T cells, injected MSC home to lymphoid organs 
where they cluster around T cells, and ameliorate the disease onset (Gerdoni et al., 2007). In 
this setting, MSC induce peripheral tolerance, impairing both the cellular and humoral arm 
of the encephalitogenic immune response, without evidence of transdifferentiation into 
neural cells (Zappia et al., 2005; Gerdoni et al., 2007). Furthermore, in a murine model of 
rheumatoid arthritis MSC have been demonstrated to exert an immunemodulatory effect by 
educating antigen-specific regulatory T cells (Augello et al., 2007). MSCs are also able to 
inhibit autoreactive T and B cells in experimental models of systemic lupus erythematosus 
(Deng et al., 2005). Overall, studies on murine models of type 1 diabetes (Fiorina et al., 2009; 
Madec et al., 2009) and multiple sclerosis (Zappia et al., 2005) as well as non-autoimmune 
diseases (Herrera et al., 2007) indicate that a key feature of MSC is their ability to selectively 
migrate into sites of injury, where they are likely to interact with activated T cells. 
Diabetogenic T cells are generated in pancreatic lymph nodes where they are introduced to 
antigens by dendritic cells. The preferential homing of MSC to pancreatic lympho nodes 
(Fiorina et al., 2009; Madec et al., 2009), supports the hypothesis that these cells could 
directly suppress autoreactive T cells in vivo within the pancreatic environment. Further, the 
desired therapeutic effects could be achieved by modulation of chemokines/receptors to 
promote the homing of MSC to specific anatomical sites (Sackstein et al., 2008). The first 
report on transplantation of human allogenic MSC, into a patient with autoimmune 
systemic sclerosis, indicates its safety and, notably, striking efficacy by selective 
immunesuppression and regeneration of impaired endothelial progenitors (Christopeit et 
al., 2008). Thus, results on the use of MSC infusion for treatment of severe graft-versus-host 
disease or autoimmune diseases (Lazarus et al., 2005; Fouillard et al., 2003; Le Blanc et al., 
2004; Ringden et al., 2006; Christopeit et al., 2008) suggest a potential use in patients at risk 
of type 1 diabetes or at disease onset, to preserve or reduce loss of ß cells (Abdi et al., 2008;  
Staeva-Vieira et al., 2007). 
7. MSC treatment of complications of diabetes mellitus 
The ability of MSC to differentiate into tissue of mesodermal origin makes them attractive 
also as therapeutic agents for a number of complications of diabetes, including 
cardiomyopathy, nephropathy, polyneuropathy and diabetic wounds. MSC have been 
shown to differentiate into several cell types, including cardiomyocytes, endothelial cells, 
neurons, hepatocytes, epithelial cells and adipocytes, characteristics coupled with capacity 
of self renewal. 
Chronic hyperglycemia is responsible for myocardial remodelling leading to ventricular 
dysfunction with hypertrophy and apoptosis of cardiomyocytes, microcirculatory defects, 
altered extracellular matrix and matrix metalloproteinasis (Jesmin et al., 2003). MSC can 
induce myogenesis and angiogenesis by different mitogenic, angiogenic and antiapoptotic 
factors, such as VEGF, IGF-1 and HGF (Zhang et al., 2008). In a diabetic rat model, 
intravenous MSC have been shown to improve cardiac function, potentially by 
differentiation into cardiomyocytes and improvement of myogenesis and angiogenesis. 
Metalloproteinase activity was also modulated, leading to increased arteriolar density and 
decreased collagen volume. Cardioprotection is probably more mediated by release of 
paracrine factors by MSC. These include VEGF, HGF,  Bcl-2, Hsp20, activation of Akt 
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(Wang et al., 2009), which can affect remodelling, repair and neovascularization. 
Intravenous autologous MSC in post-infarction patients have indeed been shown to 
reduce episodes of ventricular tachycardia and to increase ventricular ejection fraction 
(R.H. Lee et al., 2010). 
Diabetic limb ischemia could also be improved by MSC-derived pro-angiogenic factors 
(Comerota et al., 2010). 
MSC have also been used for treatment of diabetic nephropathy in NOD/SCID and 
streptozocin C57B1/6 mice (R.H. Lee et al., 2006). The injected cells engraft in damaged 
kidneys, potentially differentiate into renal cells and endothelial cells and can regulate the 
immune response. This resulted in improved kidney function and regeneration of 
glomerular structure. MSC, however, were unable to proliferate; therefore, it is conceivable 
that MSC contribute to the repair by releasing paracrine factors that promote 
neovasculatization and limit cytotoxic injury. 
As for diabetic polyneuropathy, in diabetic rats, intramuscular injection of MSC led to 
increased ratio of capillaries to muscle fibers, improvement of hyperalgesia and function of 
neural fibers. MSC settled in the gap between muscle fibers at the transplanted site, and 
produced VEGF and basic bFGF, without differentiating into neural cells (Shibata et al., 
2008). 
By releasing paracrine factors and by differentiation into photoreceptor and glial-like cells in 
the retina, transplanted MSC have also been shown to improve the integrity of the blood-
retinal barrier, ameliorating diabetic retinopathy in streptozocin diabetic rats (Z. Yang et al., 
2010). 
Prolonged and uncompleted wound healing can complicate the diabetic condition. Injection 
of MSC in animal models of diabetes improved wound healing, with increase of collagen 
levels and of wound-breaking strength, together with  increased levels of TFG, KGF, EGF, 
PDGF, VEGF, all involved in repair (Wu et al., 2007). Besides these paracrine effects  MSC 
were shown to differentiate and regenerate damaged epithelium. 
Limitation of the potential therapeutic use of MSC also for diabetic chronic complications 
are, at present, mainly the poor engraftment and the limited differentiation under in vivo 
conditions, together with the potential differentiation into unwanted mesenchymal 
lineages.  
8. Conclusion 
A number of issues should be addressed before a cell based therapy may come to a clinical 
setting. The first challenge is to define which kind of cells are more suitable for  cell 
substitution. This implies to develop efficient strategies of stem cell differentiation that lead 
to cells that produce and secrete insulin in physiological amounts under the control of 
glycemia. Moreover, safety of a cell based therapy remains a critical point, as any precursor 
or stem cell types might induce tumor formation. Whether the achievement of fully 
differentiated cells would reduce this risk remains to be proved. Another relevant point is to 
define the strategies that allow an immune modulation to avoid the recurrence of 
autoimmune destruction of newly formed  cells. 
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